Sunstone Life Science Ventures
VC Fund
Copenhagen, Denmark
Sunstone Life Science Ventures is a European, early-stage VC investing in novel pharmaceutical ingredients for human therapeutic use
- Total investments:
- 63
- Last investment:
- Lead investor:
- 16%
- Fund size:
- $92M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sunstone Life Science Ventures invests in
Stages Sunstone Life Science Ventures invests in
Countries Sunstone Life Science Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $5.5M–$61M
- Series B
- $9.5M–$58M
Investment Focus
Industry
- Biotechnology 23 (37%)
- Health Care 22 (35%)
- Medical 14 (22%)
- Therapeutics 10 (16%)
- Pharmaceutical 9 (14%)
Stage
- Series A 12 (19%)
- Series B 11 (17%)
- Funding Round 9 (14%)
- Series C 8 (13%)
- Venture - Series Unknown 4 (6%)
Country
- Denmark 13 (21%)
- Sweden 4 (6%)
- Switzerland 4 (6%)
- France 2 (3%)
- Germany 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Claus A. Andersson
General Partner
|
General Partner | Total investments: 5 | Find email | |
Jacob Lange Moresco
Investment Director
|
Investment Director | Total investments: 2 | Find email | |
Line Jacobsen
Management Assistant
|
Management Assistant | Total investments: 0 | Find email | |
Peter Benson
Chairman and Managing Partner
|
Chairman and Managing Partner | Total investments: 2 | Find email | |
Merete Lundbye Møller
Partner, General Counsel
|
Partner, General Counsel | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS). | $112.3M / Series A / Aug 19, 2026 | ||
| TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M / Series A / Dec 16, 2025 | ||
| Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | ||
Resalis Therapeutics
|
Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche | $10.9M / Series A / Jan 04, 2024 | |
| Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS). | $61M / Series A / Nov 07, 2023 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M / Oct 11, 2023 | ||
| DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $36.8M / Series A / May 10, 2023 | ||
| Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark. | $30M / Series A / Mar 14, 2023 | ||
| Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | Series B / Jan 25, 2023 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | ||
| See all 63 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sunstone Life Science Ventures invest in?
Sunstone Life Science Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 63 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sunstone Life Science Ventures invest in?
Sunstone Life Science Ventures typically joins rounds of $5.5M–$61M at Series A and $9.5M–$58M at Series B. These are whole funding-round sizes, not Sunstone Life Science Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sunstone Life Science Ventures took part in.
How do I contact Sunstone Life Science Ventures?
Public channels for Sunstone Life Science Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sunstone Life Science Ventures?
The team at Sunstone Life Science Ventures includes Claus A. Andersson (General Partner), Jacob Lange Moresco (Investment Director) and Line Jacobsen (Management Assistant), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
